Stock Alert: Ovid Therapeutics Rises 6% After Partnering With Angelini Pharma

Shares of Ovid Therapeutics Inc. (OVID) are climbing more than 6% Monday morning after the company said it has entered into an agreement with an Italian family-owned drug company, Angelini Pharma S.p.A. to manufacture and commercialize Ovid's OV101.

As per the agreement, Angelini Pharma obtains the rights to make and sell OV101 (gaboxadol), for the potential treatment of Angelman syndrome in the European Union and other countries in the European Economic Area, and also Switzerland, Turkey, the United Kingdom, and Russia.

According to the deal, Ovid will receive an upfront payment of $20 million and is eligible to receive up to an additional $212.5 million in payments upon the achievement of development, manufacturing, and sales milestones for the initial indication (Angelman syndrome). Ovid will retain commercial rights to OV101 and is also eligible for double-digit royalties on net sales if the drug is successfully sold.

Ovid stock is currently trading at $7.97. It has traded in the range of $1.74- $9.40.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Biotech Investor.
Editors Pick
Sandoz, Inc., an unit of Novartis AG, is recalling one lot of deep vein thrombosis (DVT) medication Enoxaparin Sodium in the form of injection for the potential exposure to high temperatures that may have impacted product effectiveness, the U.S. Food and Drug Administration or FDA said in a statement. Livia Global, Inc., a health and wellness company, is recalling two lots of its Liviaone liquid probiotics citing the possibility of contamination by Pseudomonas aeruginosa, the U.S. Food and Drug Administration said. Pseudomonas aeruginosa is a microorganism found in the environment that, if ingested, can cause life-threatening infection in immunocompromised individuals. United Airlines operated Thursday the first ever passenger flight using 100% Sustainable Aviation Fuel or SAF as part of its efforts to combat climate change. The airline flew the green flight from Chicago's O'Hare International Airport or ORD to Washington, D.C.'s Reagan National Airport or DCA with more than 100 passengers.
Follow RTT